Physician profile
Matthew Fackrell
NPI 1215968045
$5,077.64
in general payments reported to CMS, 2019-2025
43 companies · $999 in 2025
The $999 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $574 · 2021: $921 · 2022: $757 · 2023: $667 · 2024: $573 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,239.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,064.00 | 2020-2025 | |
| Novo Nordisk INC | $414.23 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $399.15 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $215.78 | 2019-2021 | |
| Allergan, INC. | $202.59 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $200.65 | 2025 | Fanapt |
| Pfizer INC. | $190.20 | 2020-2025 | |
| Abbott Laboratories | $189.91 | 2019-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $170.77 | 2019-2025 | Spravato |
| Phathom Pharmaceuticals, INC. | $169.83 | 2024-2025 | Voquezna |
| Insulet Corporation | $159.23 | 2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.20 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $144.19 | 2021-2025 | |
| Glaxosmithkline, LLC. | $134.04 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.27 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Fackrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.